1.90Open1.90Pre Close0 Volume4 Open Interest5.00Strike Price0.00Turnover211.20%IV10.66%PremiumDec 20, 2024Expiry Date1.53Intrinsic Value100Multiplier28DDays to Expiry0.37Extrinsic Value100Contract SizeAmericanOptions Type-0.6306Delta0.1878Gamma1.83Leverage Ratio-0.0134Theta-0.0026Rho-1.15Eff Leverage0.0036Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet